Skip to main content

Advertisement

Table 1 Association of IL-32θ mRNA expression and clinical characteristics of breast cancer patients

From: Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer

Characteristic Total IL-32θ expression P-value
Positive n (%) Negative n (%)
n = 90 n = 35 n = 55  
Age
  > 60 9 4 (44.4) 5 (55.6) 0.7553b
  ≤ 60 81 31 (38.3) 50 (61.7)
Tumor status
 T0–1 29 16 (55.1) 13 (44.8) 0.0361a
 T2–3 61 19 (31.1) 42 (68.9)
Nodal status
 N0–1 74 28 (37.8) 46 (62.2) 0.8036a
 N2–3 16 7 (43.8) 9 (56.3)
Metastasis status
 Yes 3 0 (0) 3 (100) 0.1674b
 No 87 35 (40.2) 52 (59.8)
Estrogen receptor (ER)
 Positive 64 18 (28.1) 46 (71.9) 0.001a
 Negative 26 17 (65.4) 9 (34.6)
Progesterone receptor (PR)
 Positive 53 14 (26.4) 39 (73.6) 0.0037a
 Negative 37 21 (56.8) 16 (43.2)
Human epidermal growth factor receptor 2 (HER-2)
 Positive 56 17 (30.4) 39 (69.6) 0.0331a
 Negative 34 18 (52.9) 16 (47.1)
Molecular classification
 Luminal A (ER+ PR+/− HER-2- Ki67 low) 20 9 (45) 11 (55) 0.04a
 Luminal B (ER+ PR+/− HER-2+/Ki67 high) 44 11 (25) 33 (75)
 Basal-like (ER- PR- HER-2- EGFR+/Ki67 high) 14 9 (64.3) 5 (35.7)
 HER2-enriched (ER-PR-HER-2+ Ki67 high) 12 6 (50) 6 (50)
  1. Data are presented as number of patients. EGFR, epidermal growth factor receptor. aChi square test. bFisher exact test